Skip to main content
. 2017 Dec 19;9(10):8957–8971. doi: 10.18632/oncotarget.23420

Table 1. Correlation between GSTP1 and clinicopathologic features in 237 HCC patients.

Variable (missing cases) Cases GSTP1 P-value
- + ++ +++
Gender 0.529
 Female 24(10.1%) 1(4.2%) 7(29.1%) 10(41.7%) 6(25%)
 Male 213(89.9%) 25(11.7%) 52(24.5%) 92(43.2%) 44(21.6%)
Age 0.07
 ≤ 50 ys 112(47.3%) 16(14.2%) 30(26.8%) 46(41.1%) 20(17.9%)
 >50 ys 125(52.7%) 10(8%) 29(23.2%) 56(44.8%) 30(24%)
HBsAg (3) 0.217
 Negative 37(15.8%) 4(10.8%) 7(18.9%) 15(40.6%) 11(29.7%)
 Positive 197(84.2%) 22(11.2%) 52(26.4%) 85(43.1%) 38(19.3%)
Preoperative serum AFP (2) 0.003**
 ≤ 400 ng/ml 78(32.8%) 2(2.6%) 20(25.6%) 32(41%) 24(30.8%)
 >400 ng/ml 157(67.2%) 24(15.4%) 39(24.8%) 69(43.9%) 25(15.9%)
Tumor Number 0.639
 Single 185(78.1%) 20(10.8%) 47(25.4%) 81(43.8%) 37(20%)
 Multiple 52(21.9%) 6(11.5%) 12(23.1%) 21(40.4%) 13(25%)
Tumor size 0.013*
 ≤ 3 cm 50(21%) 3(6%) 10(20%) 23(46%) 14(28%)
 3-5 cm 59(25%) 5(8.6%) 14(23.7%) 25(42.3%) 15(25.4%)
 > 5 cm 128(54%) 18(14.1%) 35(27.3%) 54(42.2%) 21(16.4%)
Edmondson-Steiner grade 0.475
 I 2(0.8%) 0(0%) 0(0%) 1(50%) 1(50%)
 II 17(7.2%) 0(0%) 6(35.3%) 9(52.9%) 2(11.8%)
 III-IV 218(92%) 26(11.9%) 53(24.3%) 92(42.2%) 47(21.6%)
PVTT 0.299
 Absent 87(36.7%) 7(8.1%) 19(21.8%) 43(49.4%) 18(20.7%)
 Present 150(63.3%) 19(12.7%) 40(26.7%) 59(39.3%) 32(21.3%)
Liver cirrhosis 0.744
 No 80(33.6%) 7(8.8%) 18(22.4%) 41(51.3%) 14(17.5%)
 Yes 157(66.4%) 19(12.1%) 41(26.1%) 61(38.9%) 36(22.9%)
TNM 0.462
 I 75(31.5%) 7(9.3%) 15(20%) 39(52%) 14(18.7%)
 II 130(55.1%) 14(10.8%) 36(27.7%) 51(39.2%) 29(22.3%)
 III-IV 32(13.4%) 5(15.6%) 8(25%) 12(37.5%) 7(21.9%)
*

P<0.05, **P<0.01, have statistical significance.